Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma

Stem Cells

Volumn 27, Issue 7, 2009, Pages 1487-1495

  He, Xiaobing ^a   Marchionni, Luigi ^a   Hansel, Donna E ^b   Yu, Wayne ^a   Sood, Akshay ^a   Yang, Jie ^a   Parmigiani, Giovanni ^a   Matsui, William ^a   Berman, David M ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Differentiation; Malignancy; Stem cell microenvironment interactions; Stromal cells

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CYTOKERATIN 17; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE; LAMININ RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL CELL; CANCER GROWTH; CANCER MORTALITY; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL HETEROGENEITY; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; FOCAL ADHESION; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TUMOR CELL; TUMOR XENOGRAFT; UROGENITAL TRACT CANCER;

AGED; ANIMALS; ANTIGENS, CD; CARCINOMA, TRANSITIONAL CELL; CELL ADHESION MOLECULES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-17; MICE; MICE, NUDE; RECEPTORS, LAMININ; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS; URINARY BLADDER NEOPLASMS; UROTHELIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMALIA; MOUSE MAMMARY TUMOR VIRUS;

EID: 68049148065     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.92     Document Type: Article

References (58)

1. Kurzrock EA, Lieu DK, Degraffenried LA et al. Label-retaining cells of the bladder: Candidate urothelial stem cells. Am J Physiol Renal Physiol 2008;294:F1415-F1421.
2. Farsund T. Cell kinetics of mouse urinary bladder epithelium. II. Changes in proliferation and nuclear DNA content during necrosis regeneration, and hyperplasia caused by a single dose of cyclophosphamide. Virchows Arch B Cell Pathol 1976;21:279-298.
3. Lewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol 2000;278:F867-F874. (Pubitemid 30441352)
4. Jemal A, Thun MJ, Ries LA et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-1694.
5. Lobo NA, Shimono Y, Qian D et al. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007;23:675-699.
6. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
7. Jordan CT. Cancer stem cells: Controversial or just misunderstood? Cell Stem Cell 2009;4:203-205.
8. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
9. Wang JC, Dick JE. Cancer stem cells: Lessons from leukemia. Trends Cell Biol 2005;15:494-501. (Pubitemid 41253469)
10. Sun TT, Eichner R, Nelson WG et al. Keratin classes: Molecular markers for different types of epithelial differentiation. J Invest Dermatol 1983;81:109s-115s.
11. Grubb C, Janota I. Squamous differentiation in carcinoma in situ of the cervix uteri. A cyto-histological correlation of malignant intraepithelial lesions with invasive carcinoma. J Clin Pathol 1967;20:7-14.
12. Huang HY, Shariat SF, Sun TT et al. Persistent uroplakin expression in advanced urothelial carcinomas: Implications in urothelial tumor progression and clinical outcome. Hum Pathol 2007;38:1703-1713.
13. Li SM, Zhang ZT, Chan S et al. Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol 1999;162:931-935. (Pubitemid 29436920)
14. Seraj MJ, Thomas AR, Chin JL et al. Molecular determination of perivesical and lymph node metastasis after radical cystectomy for urothelial carcinoma of the bladder. Clin Cancer Res 2001;7:1516-1522.
15. Brabletz T, Jung A, Spaderna S et al. Opinion: Migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744-749. (Pubitemid 41486367)
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
17. Fedor HL, De Marzo AM. Practical methods for tissue microarray construction. Methods Mol Med 2005;103:89-101.
18. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
19. Gentleman RC, Carey VJ, Bates DM et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
20. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods 2003;31:265-273.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B 1995;57:289-300.
22. Irizarry RA, Bolstad BM, Collin F et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
23. Ashburner M, Ball CA, Blake JA et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-29.
24. Kanehisa M. The KEGG database. Novartis Found Symp 2002;247:91-101; discussion101-113,119-128,244-252.
25. Kleeberger W, Bova GS, Nielsen ME et al. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res 2007;67:9199-9206. (Pubitemid 47535906)
26. Kiyoshima K, Oda Y, Kinukawa N et al. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: Association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2. Hum Pathol 2005;36:522-530.
27. Diggle CP, Cruickshank S, Olsburgh JD et al. Identification of genes up-regulated in urothelial tumors: The 67-kd laminin receptor and tumor-associated trypsin inhibitor. Am J Pathol 2003;163:493-504. (Pubitemid 36909412)
28. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973-978. (Pubitemid 46154721)
29. Yang YM, Chang JW. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: Novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest 2008;26:725-733.
30. Schaeffer EM, Marchionni L, Huang Z et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene 2008;27:7180-7191.
31. Golubovskaya VM, Nyberg C, Zheng M et al. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the Y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008;51:7405-7416.
32. Kim BH, Yin CH, Guo Q et al. A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells. Mol Cancer Ther 2008;7:2672-2680.
33. Rizzo P, Osipo C, Foreman K et al. Rational targeting of Notch signaling in cancer. Oncogene 2008;27:5124-5131.
34. Xue Q, Hopkins B, Perruzzi C et al. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 2008;68:9551-9557.
35. Wakeling AE. Inhibitors of growth factor signalling. Endocr Relat Cancer 2005;12(Suppl 1):S183-S187.
36. Chen B, Dodge ME, Tang W et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-107.
37. Nusse R. Wnt signaling and stem cell control. Cell Res 2008;18:523-527. (Pubitemid 351630946)
38. Urakami S, Shiina H, Enokida H et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res 2006;12:2109-2116.
39. Urakami S, Shiina H, Enokida H et al. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res 2006;12:383-391. (Pubitemid 43166125)
40. Stoehr R, Krieg RC, Knuechel R et al. No evidence for involvement of beta-catenin and APC in urothelial carcinomas. Int J Oncol 2002;20:905-911.
41. Cselenyi CS, Lee E. Context-dependent activation or inhibition of Wnt-beta-catenin signaling by Kremen. Sci Signal 2008;1:pe10.
42. Hassler C, Cruciat CM, Huang YL et al. Kremen is required for neural crest induction in Xenopus and promotes LRP6-mediated Wnt signaling. Development 2007;134:4255-4263.
43. Crawford HC, Fingleton BM, Rudolph-Owen LA et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-2891.
44. He TC, Sparks AB, Rago C et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512. (Pubitemid 28425575)
45. Gao S, Eiberg H, Krogdahl A et al. Cytoplasmic expression of E-cadherin and beta-Catenin correlated with LOH and hypermethylation of the APC gene in oral squamous cell carcinomas. J Oral Pathol Med 2005;34:116-119.
46. Kastan MB, Schlaffer E, Russo JE et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990;75:1947-1950.
47. Berberat PO, Dambrauskas Z, Gulbinas A et al. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res 2005;11:3790-3798. (Pubitemid 40685598)
48. Eisele L, Klein-Hitpass L, Chatzimanolis N et al. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia. Acta Haematol 2007;117:8-15. (Pubitemid 46012418)
49. Josson S, Xu Y, Fang F et al. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 2006;25:1554-1559. (Pubitemid 43361940)
50. Dyrskjot L, Kruhoffer M, Thykjaer T et al. Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004;64:4040-4048. (Pubitemid 38697320)
51. Dyrskjot L, Thykjaer T, Kruhoffer M et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90-96. (Pubitemid 36068689)
52. Stransky N, Vallot C, Reyal F et al. Regional copy number-independent deregulation of transcription in cancer. Nat Genet 2006;38:1386-1396. (Pubitemid 44837560)
53. Als AB, Dyrskjot L, von der Maase H et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007;13:4407-4414. (Pubitemid 47219707)
54. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. New Engl J Med 2007;356:217-226. (Pubitemid 46143225)
55. Kern SE, Shibata D. The fuzzy math of solid tumor stem cells: A perspective. Cancer Res 2007;67:8985-8988. (Pubitemid 47535878)
56. Luna MA, el Naggar A, Parichatikanond P et al. Basaloid squamous carcinoma of the upper aerodigestive tract. Clinicopathologic and DNA flow cytometric analysis. Cancer 1990;66:537-542.
57. Schneider BP, Winer EP, Foulkes WD et al. Triple-negative breast cancer: Risk factors to potential targets. Clin Cancer Res 2008;14:8010-8018.
58. Adley BP, Yang XJ. Alpha-methylacyl coenzyme A racemase immunoreactivity in partial atrophy of the prostate. Am J Clin Pathol 2006;126:849-855.